New Study Links Fosamax to Esophageal Cancer

According to the abstract of the study published in June 2012 at the meeting of the American Society of Clinical Oncology in Chicago, researchers from Northwestern University in Chicago indicated that use of Fosamax was linked to a higher rate of esophageal cancer when compared to people who took similar drugs, known as bisphosphonates. Fosamax, manufactured by Merck, is a drug approved by the FDA in 1995 to treat post-menopausal osteoporosis and Paget's disease of bone. Now, AttorneyOne.com, a recognized authority on law, can provide helpful, proven advice and simple solutions including how to get in contact with legal counsel so anyone can easily and inexpensively deal with cases of Fosamax severe adverse events. [http://www.attorneyone.com/fosamax-lawsuit/ .

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Fosamax: severe adverse events threat

Fosamax: severe adverse events threat

Fosamax (alendronate) accounted for 75% of the esophageal cancers seen with bisphosphonates in the FDA database

San Diego, CA (PRWEB) July 12, 2012

The media spotlight is often a double-edged sword. No one knows this better than people who filed a Fosamax Lawsuit. And yet, gossip and rumor-mongering aside, the real story here is being overlooked according to Sean Burke of AttorneyOne.

According to the abstract of the study published in June 2012 at the meeting of the American Society of Clinical Oncology in Chicago, researchers from Northwestern University in Chicago indicated that use of Fosamax was linked to a higher rate of esophageal cancer when compared to people who took similar drugs, known as bisphosphonates. Fosamax, manufactured by Merck, is a drug approved by the FDA in 1995 to treat post-menopausal osteoporosis and Paget's disease of bone.

Researchers searched the FDA Adverse Event Reporting System (AERS) database using terms related to esophageal cancer combined with all drug names for bisphosphonates (search period:1996-2010) and, overall, 128 cases of bisphosphonate-associated esophageal cancer were reported. As MedPage Today reported, Fosamax (alendronate) accounted for 75% of the esophageal cancers seen with bisphosphonates in the FDA database -- 6.4 times more than with any other drug in the class.

AttorneyOne.com, a recognized authority on law, can provide helpful advice and simple solutions including how to get in contact with legal counsel so that, in case of severe adverse events from Fosamax, someone can easily and inexpensively deal with it. As Mr. Burke, director of Media Relations for AttorneyOne.com, added, “What all this information really illustrates is that threat from Fosamax remains. For that reason, our focus should squarely fall on getting the word out and assisting people in finding the right legal assistance.”

According to the article published in the Wall Street Journal on May 21st, 2012, Merck & Co. faces more than 3,100 product-liability lawsuits, including 1,200 alleging Fosamax caused jaw bones to decay in some patients, based on a recent filing it made with the Securities and Exchange Commission.

AttorneyOne.com has further information on Fosamax lawsuits including how to get in contact with legal counsel.

Headquartered in San Diego, CA Attorney One was founded in 2004 and is not a law firm. They offer a nationwide legal service which helps consumers find the best representation for their legal needs. You can learn more about Attorney One at our website http://www.attorneyone.com. You can also find us on Facebook at http://www.facebook.com/AttorneyOne. Checkout earlier news from us at http://www.prweb.com/releases/2012/7/prweb9672790.htm.